Skip to content

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Francisco Moreno, Christopher B. Wiegand, E. Keolani Taitano, Pedro L. Delgado

The Journal of Clinical Psychiatry November 15, 2006 DOI: 10.4088/jcp.v67n1110 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Controlled clinical trial Peer reviewed
Population Subjects with obsessive-compulsive disorder (OCD)
Intervention Psilocybin
Topics Anxiety Psilocybin
Keywords Tolerability Hallucinogen Adverse effect Obsessive compulsive Visual analogue scale Anesthesia Obsessive-compulsive spectrum disorders
Citations 786
Key findings Psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.

Abstract

In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.

In the evidence

This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.

  • State of the evidence: Psilocybin for anxiety Supports

    Psilocybin was safely used and associated with acute reductions in core OCD symptoms in several subjects.

    Synthesized

  • State of the evidence: Anxiety Supports

    Psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.

    Synthesized

Comparable studies

Other non-randomized and open-label trials on psilocybin for anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study
Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience Male long-term AIDS survivors with moderate-severe demoralization 2020 Open-label trial n = 18
Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial Patients with a DSM-5 depressive disorder associated with a cancer diagnosis 2023 Open-label feasibility and safety pilot study

Related reading

Explore topics

Anxiety Psilocybin

By condition and practice

Psilocybin for anxiety